Please use this identifier to cite or link to this item:
Title: Novel and emerging therapeutics for genetic epilepsies
Authors: Pejcic, Ana
Jankovic, Slobodan
Đešević M.
Gojak R.
Lukic, Snezana
Marković N.
Milosavljević, Miloš
Issue Date: 2021
Abstract: Introduction: Disease-specific treatments are available only for a minority of patients with genetic epilepsies, while the rest are treated with anticonvulsants, which are ineffective in almost one-third of patients. Areas covered: Recently approved and the most effective emerging therapeutics under development for the treatment of genetic epilepsies are overviewed after systematic search and analysis of relevant literature. Expert opinion: New and emerging drugs for genetic epilepsies exploit one of the two approaches: inhibiting hyperactive brain foci through blocking excitatory or augmenting inhibitory neurotransmission, or correcting the underlying genetic defect. The first is limited by insufficient selectivity of available compounds, and the second by imperfection of currently used vectors of genetic material, unselective and transient transgene expression. Besides, the treatment may come too late, after structural abnormalities and epilepsy deterioration takes place. However, with recent improvements, we can expect to see soon gradual decline in the number of patients with therapy-resistant genetic epilepsies.
Type: article
DOI: 10.1080/14737175.2021.1992275
ISSN: 1473-7175
SCOPUS: 2-s2.0-85118121820
Appears in Collections:Faculty of Medical Sciences, Kragujevac

Page views(s)




Files in This Item:
File Description SizeFormat 
  Restricted Access
29.86 kBAdobe PDFThumbnail

Items in SCIDAR are protected by copyright, with all rights reserved, unless otherwise indicated.